Business EconomyPosted at: Nov 6 2025 10:55PM

Bengaluru, Nov 6 (UNI) Pharma maker Senores Pharmaceuticals Ltd today announced that its net profit for the second quarter (Q2) ended September 30, 2025, stood at Rs 30 crore, jumping by 131 percent as compared to Rs 13.1 crore during the corresponding quarter of last fiscal year, driven by growth across its regulated, emerging and branded generics businesses.
Similarly, the company has reported consolidated revenue of Rs 162 crore (USD 19.5 million), up by 61 pc from a year earlier.
Earnings before interest, taxes, depreciation, and amortization (EBITDA) also rose by 113 pc to Rs 50 crore, the company said.
For the first half of FY26, net profit edged higher by 114 pc to Rs 51 crore and revenue climbed 66 pc to Rs 300 crore, while EBITDA increased by 88 pc to Rs 84 crore.
Revenue from regulated markets grew 87 pc year-on-year in Q2, supported by the company's ANDA portfolio and operational efficiencies, with EBITDA margin improving to 44% from 36% in the previous quarter.
Senores launched eight new products during the quarter, taking its total to 32 commercial products, 81 approved ANDAs, and 70 in the pipeline. Its CDMO/CMO business also expanded with 32 commercial products and 45 under development.
The emerging markets segment, spanning more than 40 countries, contributed Rs 32 crore in Q2 and Rs 61 crore in H1, maintaining an EBITDA margin of around 6 pc. The company currently has 394 approved products and 824 under registration in these markets.
In India, the branded generics business saw revenue increase more than tenfold in Q2 and sevenfold in H1, with approvals from leading hospitals and a nationwide rollout planned by end of FY26.
Swapnil Shah, Managing Director, said: "Building on previous momentum, we delivered strong revenue and profitability growth. Regulated markets remain a key driver, supported by our ANDA portfolio and CDMO pipeline. The branded generics business is scaling rapidly, with traction from major hospitals. We are confident of sustaining this momentum through FY26 and beyond."
Senores continues to focus on expanding its ANDA portfolio, scaling CDMO/CMO operations, diversifying emerging markets, and broadening branded generics in India. Investments in R&D and manufacturing capacity are expected to support growth and margin improvements over the medium term. UNI BDN SS

Please log in to get detailed story.